Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome
Latest Information Update: 21 Jul 2022
At a glance
- Drugs Infliximab (Primary) ; Tocilizumab (Primary)
- Indications COVID-19 pneumonia; COVID-19 respiratory infection; Cytokine release syndrome
- Focus Therapeutic Use
- 19 Jul 2022 Status changed from recruiting to completed.
- 08 Feb 2021 New trial record